Clinical observation of low-dose dexmedetomidine combined with butorphanol tartrate for patient controlled intravenous analgesia after radical mastectomy
10.3760/cma.j.issn.1673-4904.2013.27.012
- VernacularTitle:低剂量右美托咪定复合酒石酸布托啡诺用于乳腺癌根治术后静脉镇痛的临床观察
- Author:
Daipeng ZHOU
- Publication Type:Journal Article
- Keywords:
Analgesia,patient-controlled;
Dexmedetomidine;
Butorphanol;
Radical mastectomy
- From:
Chinese Journal of Postgraduates of Medicine
2013;36(27):33-35
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical effect of low-dose dexmedetomidine combined with butorphanol tartrate for patient controlled intravenous analgesia (PCIA) after radical mastectomy.Methods Seventy patients who ASA classification Ⅰ-Ⅱ grades with elective radical mastectomy were divided into the butorphanol tartrate PCIA group (group B),and the dexmedetomidine combined with butorphanol tartrate PCIA group (group DB) with 35 cases each by to random digits table method.To compare two groups of 24 h and 48 h after surgery in patients with pain score by visual analog scale (VAS) scores (0-10 scores).The Ramsay scores and the butorphanol consumption,intramuscular pethidine times were recorded in two groups.And the adverse events such as nausea and vomiting,dizziness and respiratory depression were observed.Results All patients got good analgesia in two groups,VAS scores ＜ 4 scores.VAS scores at 24,48 h after operation in group DB were lower than those in group B [(3.2 ± 0.3) scores vs.(3.8 ± 0.4) scores,(2.7 ± 0.3) scores vs.(3.2 ±0.2) scores],there were significant differences (P ＜0.05),while there was no significant difference of Ramsay scores between two groups(P＞ 0.05).And the butorphanol consumption and the intramuscular pethidine times in group DB were less than those in group B [(6.2±1.3)mgvs.(7.8± 1.6) mg,(2.3 ±1.8) times vs.(5.3 ±2.1) times],there were significant differences (P ＜0.05).Conclusion Low-dose dexmedetomidine may improve the effect of butorphanol tartrate PCIA after radical mastectomy,and help to reduce the butorphanol tartrate consumption and adverse effects.
